Intravenous (IV) paclitaxel is approved for the treatment of numerous cancers including MBC. Oraxol (Athenex, USA), is an oral formulation of paclitaxel in combination with a novel, orally active, potent and specific inhibitor of P-gp (HM30181A). Oraxol is expected to be less toxic with comparable efficacy to its iv counterpart. We report the interim results of an ongoing study of Oraxol in MBC patients.
|期刊||Annals of Oncology|
|出版狀態||已發佈 - 十月 21 2018|
DAI, M., Chao, T-Y., Chao, T., Chiu, C., Lu, Y., Shiah, H., Wu, Y., Gerald Fetterly, G., Hung, N., Cutler, D. L., Kwan, R., Douglas Kramer, D., Chan, W., & Hung, T. (2018). Oral paclitaxel and HM30181A demonstrate clinical activity in metastatic breast cancer (MBC) patients. Annals of Oncology. https://oncologypro.esmo.org/Meeting-Resources/ESMO-2018-Congress/Oral-paclitaxel-and-HM30181A-demonstrate-clinical-activity-in-metastatic-breast-cancer-MBC-patients